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Standard cancer treatments involve surgery, radiotherapy, chemotherapy, and
immunotherapy. In clinical practice, the respective drugs are applied orally or
intravenously leading to their systemic circulation in the whole organism. For
chemotherapeutics or immune modulatory agents, severe side effects such as immune
depression or autoimmunity can occur. At the same time the intratumoral drug
doses are often too low for effective cancer therapy. Since monotherapies frequently
cannot cure cancer, due to their synergistic effects multimodal therapy concepts
are applied to enhance treatment efficacy. The targeted delivery of drugs to the
tumor by employment of functionalized nanoparticles might be a promising solution
to overcome these challenges. For multimodal therapy concepts and individualized
patient care nanoparticle platforms can be functionalized with compounds from various
therapeutic classes (e.g. radiosensitizers, phototoxic drugs, chemotherapeutics, immune
modulators). Superparamagnetic iron oxide nanoparticles (SPIONs) as drug transporters
can add further functionalities, such as guidance or heating by external magnetic fields
(Magnetic Drug Targeting or Magnetic Hyperthermia), and imaging-controlled therapy
(Magnetic Resonance Imaging).
Keywords: nanoparticles, nanomedicine, targeted therapy, immunotherapy, chemotherapy, irradiation,
immunogenic cell death
EVOLVEMENT OF TUMORS AND THEIR TREATMENTS
Mutation and clonal selection are driving forces in carcinogenesis (1). Accumulation of mutations
in proto-oncogenes and tumor suppressor genes lead to uncontrolled proliferation of cells.
Some of these mutations are recognized by the immune system as “non-self ” (tumor associated
antigens) and are eliminated, a process known as “immunosurveillance” (2, 3). Cells expressing
only low amounts of tumor associated antigens cannot be detected and removed. Thus, the
immune system exerts a selective force on the tumor, altering cell composition and promoting
survival of the least immunogenic cells (“immunoediting”) (4). Tumors evade the immune
system by various mechanisms such as downregulation of MHC I expression, development of
resistance to cytotoxic T lymphocytes, active suppression of activated T cells, or release of immune
suppressive molecules (5). In the clinic, tumors are treated by surgery, radiotherapy, chemotherapy,
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photodynamic therapy, and others. All of these procedures can
induce the release of immune stimulatory intracellular molecules
increasing the immunogenicity of the tumor. Immunotherapies
shall further intensify the strength of immune responses.
Problematically, monotherapies often cannot remove the tumor
completely due to the occurrence of resistant tumor cell
populations. Chemotherapy can lead to multiple drug resistance
in long term use (6). In radiotherapy the lack of oxygen in
hypoxic tumor tissues results in reduced production of reactive
oxygen species (ROS) and thus decreased DNA damage (7).
Immunotherapy is often effective only in a subgroup of patients.
Thus, combinations of therapy concepts exhibiting synergistic
effects might overcome limitations of monotherapies, referred
to as multimodal tumor therapy. To bring therapeutics to the
tumor area, nanoparticles have come into focus. Serving as
transporters, various therapeutic cargos can be integrated in
one nanoparticle system to combine different functionalities.
Here we discuss the use of nanoparticles as multimodal drug
transporters with special emphasis on superparamagnetic iron
oxide nanoparticles (SPIONs). Based on their magnetic core
they can be magnetically guided to the desired place, visualized
in magnetic resonance imaging (MRI) and serve as heat
transporters in magnetic hyperthermia.
CHALLENGES OF SYSTEMIC TUMOR
THERAPIES
After intravenous or oral application of fluid chemo- and
immunotherapeutics, the drug circulates in the whole organism
and only a fraction reaches the tumor, whereas the majority
disappears in the healthy tissues or is ejected. Thus, high doses
must be applied for sufficient therapeutic concentrations in the
tumor (8). Also, poor solubility can be an obstacle to reach
effective therapeutic doses.
Chemotherapeutics are injected in a cyclic schedule to kill the
rapidly proliferating tumor cells. Problematically, not only the
tumor is affected but also healthy tissues (9) with quickly dividing
cells such as cells of the blood, the immune system, hair, or
mucosa. Since some cytostatic agents are carcinogens themselves
they sometimes induce acute myeloid leukemia after therapy (9).
Additionally, the risk of chemotherapy-associated anemia (10)
and neutropenia (11) is high. Thus, immune function must be
monitored regularly. In case of severe limitations, it may be
necessary to reduce or stop the therapy (12). If the number of
leukocytes in blood is too low, infections may occur and therefore
patients often die due to therapy-related side effects and not the
tumor itself (13).
Unlike chemotherapy, immunotherapy does not destroy
cancer cells directly. The goal of immunotherapy is to manipulate
the immune system to kill cancer without impeding normal
tissues. Since checkpoint inhibitors act by blocking the inhibition
of T cells, additionally to the wanted reactions such as tumor
infiltration and killing of cancer cells, activated T cells can
also attack healthy cells, resembling autoimmune reactions (14).
While chemotherapy is associated with immunosuppression and
infections, some of the recent approaches in immunotherapy
can be accompanied by massive inflammatory responses and
autoimmune-type like pathologies, which can affect all the
organs of the body (14, 15). For Ipilimumab therapy in
metastatic melanoma for instance, immune-mediated side effects
as dermatitis, hepatitis, enterocolitis, hypophysitis, and uveitis,
which can be life threatening, have been described (16). For
management of inflammatory side effects systemic steroids or
corticosteroids should be considered (16).
Immunotherapies are effective only in a subgroup of cancers
and a minority of patients (17, 18). Reasons for this are tumor
heterogeneity, previous treatments, variability in tumor type and
stage and immunosuppressive phenotype of the cancer (19).
Tumors with many mutations seem to have better response
rates to immune checkpoint blockade with PD-1, probably due
to higher tumor immunogenicity (20). Since immunotherapies
are not applied as first line treatments, they are rather
given to patients with compromised immune systems due to
advanced disease or previous chemotherapy cycles, hindering the
development of effective immune reactions (21).
Moreover, immunotherapies are very expensive depending on
dosing and scheduling, putting economic pressure on patient
and healthcare system (22). In 2016 the one-year per-patient
costs for treatment of metastatic melanoma with PD-1 inhibitor
Pembrozulimab was $145,010, achieving a progressing-free
survival of 6.3 month (23, 24). Combination therapies can even
double or triple the costs. These extremely expensive therapies
might be denied by health insurances or lead to restrictions for
patients who cannot afford additional payments for the drugs
(24). Also, only few of the treatments reach complete tumor
remission after one treatment cycle, so that multiple rounds of
treatments are necessary.
TARGETED THERAPIES USING
NANOPARTICLES
Systemic toxicities can hinder the efficacy of potent antitumor
drugs. However, side effects caused by the unspecific distribution
and low doses in the target area are not only problems in the
treatment of tumors but also of various other diseases. To bring
therapeutics directly to the target area and to reduce systemic
concentrations nanocarriers have come into focus.
Passive Delivery of Nanoparticles
Distribution, pharmacokinetics and retention of medical
nanoparticles strongly depend on the route of application and
the physicochemical nanoparticle characteristics. For daily
medication, oral application is comfortable for the patients.
However, orally applied nanoparticles are rather quickly excreted
from the body than being absorbed through the intestine into the
blood. A possibility to increase nanoparticle absorption from the
gastrointestinal tract is the conjugation of nanoparticles with bile
acids, employing bile acid transporter-mediated cellular uptake
and chylomicron transport pathways (25). With intravenous
application nanoparticles tend to be restricted to the vascular
system and to organs with a fenestrated endothelium, such as
liver and spleen since the pore size of normal intact endothelium
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is about 5 nm. Tumors and inflamed areas are accessible as
well, since they exhibit fenestrated endothelium and vascular
leakiness. Depending on their size, injected nanoparticles
undergo renal clearance including glomerular filtration, tubular
secretion, and finally elimination through urinary excretion.
For globular proteins the filtration-size threshold is <5 nm, and
this seems to be comparable for nanoparticles (26, 27). Larger
particles are cleared from blood circulation via phagocytic cells
of the reticuloendothelial system (RES). Macrophages in the
liver (Kupffer cells), the spleen and the circulating blood rapidly
take up opsonized nanoparticles and intracellularly degrade
them (28, 29). Importantly, systemic inflammation affects
nanoparticle distribution by alteration of systemic circulatory
properties, modulation of the immune system and increase
of vessel permeability (30). Modification of the nanoparticle
surface by polyethylene glycol (PEG) reduces non-specific
protein adsorption and opsonization and minimizes clearance
by the RES, thus resulting in longer blood circulation times
and improved pharmacokinetic properties (31). Intraarterial
injection in proximity to the tumor site can limit the nanoparticle
removal by the RES (32).
When tumors exceed a distinct size transport of oxygen and
nutrients by diffusion is insufficient and access to the blood
circulation is necessary (33). Contrary to healthy blood vessels,
tumor capillaries have large gaps between endothelial cells, a
wide irregular lumen and lack of smooth muscle cells, enabling
the selective extravasation. The poor lymphatic drainage permits
retention of macromolecular drugs or nanoparticles in the
tumor microenvironment, referred to as enhanced permeation
and retention (EPR) effect (34, 35). So far, several clinically
approved chemotherapeutics such as doxorubicin, daunorubicin,
or vincristine encapsulated into liposomes have been approved
as nanomedicines by the Federal Drug Administration (FDA).
Beside these first generation clinically approved nanomedicines,
other non-targeted nanosystems are under investigations in
clinical studies (phase I/II/III) (36).
Active Delivery of Nanoparticles
Despite preferential accumulation in tumor tissues due to the
EPR effect, the fraction of nanoparticles finally entering the
tumor is still limited. The majority of the applied nanoparticles
is removed from blood in a few hours and only some percent
remain in the systemic circulation (37). Finally, only ∼2% of
the total intravenously administered dose is deposited in the
tumor after 4 h of circulation (38). To increase the intratumoral
dose, several studies revealed receptor-based active targeting
of nanoparticles to be a promising delivery strategy (39).
Targeting ligands such as monoclonal antibodies and antibody
fragments, aptamers, peptides and small molecules are under
extensive investigation for use in diagnostics, therapy and
post-therapeutic follow-up (40). For example, Trastuzumab
functionalized nanoparticles targeting Her2 positive tumor cells
showed favorable results in experiments with breast cancer cells
as diagnostic agents and drug delivery vehicles (41, 42). SPIONs
with folic acid as targeting molecule enhanced the uptake by
folate receptor exposing tumor cells (43).
Beside use of targeting moieties, nanoparticles can be
transported by physical forces to the desired place. For instance,
SPIONs can be applied as drug transporters in Magnetic Drug
Targeting (MDT). To prevent clearance by RES, SPIONs are
applied intraarterially in the tumor supplying vascular system
and are enriched in the tumor region using an external
magnetic field. Previously, studies with tumor bearing rabbits
(squamous cell carcinoma) revealed that the amount of the
chemotherapeutic agent mitoxantrone in the tumor region can
be increased from 1% after intravenous application to 50–60%
with MDT. Complete tumor remissions or slower tumor growth
with increased survival times were shown in the majority of the
treated animals (44). Also, immune cells from peripheral blood
were spared from the toxic effects of the chemotherapy, due to
specific accumulation in the tumor (45).
A major challenge remains the treatment of tumors in the
brain, due to often being surrounded by important functional
structures, which can be injured by interventions such as
surgery, intratumoral injections or radiation. In this case,
magnetic forces can be used to trap SPIONs at the site
of interest. To bypass the first-pass organ clearance of the
magnetic nanoparticles, intraarterial administration via carotid
artery enhances nanoparticle exposure of the tumor vasculature.
Together with an MRI guided subject alignment within the
magnetic field and surface modification of the drug with
biological membrane permeable polyethyleneimine it is possible
to deliver ß-galactosidase selectively to the brain tumor in a rat
glioma model, while limiting the exposure of healthy brain areas
(32). In this approach, magnetic field topography is essential to
prevent magnetic aggregation in the vasculature (32, 46, 47).
To prevent nanoparticle aggregation and occlusion of vessels
in magnetic fields we found that a proper surface coating and
colloidal stabilization of SPIONs is a prerequisite (48).
IMMUNOGENIC CELL DEATH INDUCTION
BY TUMOR THERAPIES
Therapeutic strategy of conventional treatments relies on
the rationale that rapidly proliferating tumor cells are more
sensitive to toxic chemicals or radiation than healthy tissues.
In the past, it has been believed that these treatments
simply act by killing the tumor cells or inhibiting their
proliferation. However, it became apparent that distinct cell
death pathways activated during cell stress turn the cells
“visible” for the immune system, a process referred to as
immunogenic cell death (ICD). Agents inducing ICD in cancer
therapy are for example chemotherapeutics from the class
of the anthracyclines and their derivatives (e.g., doxorubicin,
mitoxantrone), photosensibilisators for photodynamic therapy
(PDT) or radiotherapy (49). In contrast to apoptosis, the
physiological form of cell death, eliciting inflammatory silent
or even anti-inflammatory clearance, ICD induces inflammatory
immune reactions. Hallmark of ICD is the release of damage
associated molecular patterns (DAMPs) from the dying cells in
a timely resolved fashion (50). The early cell surface exposition
of calreticulin, the active release of heat shock proteins (HSPs)
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and ATP as well as the post mortem leakage of HMGB1 have
been described to act as endogenous adjuvants, recruiting and
activating immune cells. Professional antigen presenting cells
take up tumor derived antigens, process them, migrate to the
tumor draining lymph nodes and cross present them to T cells.
Subsequently, antigen specific T cells differentiate to effector
T cells, proliferate, and are attracted to the tumor region by
chemokines (51). There, effector T cells kill the tumor cells via
cytotoxic granules or Fas-induced apoptosis and thereby create
a new wave of released tumor antigens which boost the immune
response (52). By inducing ICD radiation, photodynamic therapy
(PDT) and/or chemotherapy may activate immune responses
and immunize a patient against cancer by turning the tumor
into an in situ vaccine (53). Radiation and chemotherapy
both can induce DNA damage resulting in cell cycle arrest
and/or cell death. Furthermore, cellular mutations with the
development of neoantigens are provoked, resulting in higher
immunogenicity (Figure 1A).
NANOPARTICLE-BASED THERAPIES
Due to induction of ICD by several routine treatment regimens,
the combination of those therapies with immunotherapeutic
agents can induce or increase anti-tumor responses from the
immune system. Amultitude of various nanoparticle systems has
been developed for medical application and multimodal tumor
therapy, which are discussed elsewhere (54). SPIONs can be
tailored in size, morphology and functionalization, enabling their
use in a wide range of applications (55). SPIONs can be loaded
as drug transporters with various cargos (chemotherapeutics,
photosensibilisators, immune modulators), serve as contrast
agents in MRI, provide heating capacity in alternating magnetic
fields, and enable magnetic targeting (Figure 2). Due to
these additional possibilities, a special focus will be set on
SPIONs here.
SPIONs as Drug Transporters
Prerequisite for use of nanoparticles in biomedicine is their
biocompatibility. Due to their inorganic nature, SPIONs on
their own are not sufficiently biocompatible. One strategy to
circumvent this compatibility issue is to coat the SPIONs
with biocompatible polymers (56). For SPIONs comprehensive
studies have been performed with partially contradictory
results dependent on size, coating, applied concentration and
exposure time of the nanoparticles (57). Reported toxicities
in experimental studies include reduced mitochondrial activity,
cellular stress mediated generation of ROS, inflammation and
chromosome condensation (58). In our hands, coating of
nanoparticles with biocompatible substances such as crosslinked
dextran or formation of an artificial protein corona of serum
albumin not only increased colloidal stability of the particles
but also their biocompatibility (59–64). Some formulations of
magnetite-based nanoparticles have already been approved for
FIGURE 1 | Induction of anti-tumor immune reactions by multimodal therapy. (A) Chemotherapy, radiotherapy, and photodynamic therapy (PDT) induce immunogenic
cell death (ICD) in the tumor with release of damage associated molecular patterns (DAMPs) and tumor associated antigens (TAA). TAA are taken up by antigen
presenting cells (APC), such as dendritic cells (DCs) and are processed and presented to T cells, which are activated to proliferate. Accompanying immunotherapy
(e.g., with anti-PD-1) blocks PD-1 (on T cells) and PD-L1 (on tumor cells and APCs) interaction, resulting in immune activation and increase of anti-tumor immune
responses. (B) Integrating several treatment functionalities on one nanoparticle and active targeting to the tumor region e.g. by magnetic drug targeting (MDT) might
increase the therapeutic doses in the tumor and reduce systemic distribution with accompanying side effects such as immune deprivation.
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FIGURE 2 | SPIONs as nanoparticle platform for multimodal tumor therapy.
SPIONs can be functionalized with various cargos such as cytotoxic agents for
chemotherapy, photosensibilisators for photodynamic therapy and/or immune
modulators for immunotherapy. To increase treatment efficacy, magnetic
hyperthermia can be induced in alternating magnetic fields. Radiation induces
release of ROS on the particle surface. Imaging controlled therapy is enabled
by magnetic resonance imaging (MRI).
use in humans as iron deficiency therapeutics and as MRI
contrast agents by the FDA (e.g., Feraheme R©, Feridex I.V. R©
and Gastromark R©) (65). Once the SPIONs are administered
intravenously, they enter liver and spleen (66). SPIONs are
taken up into the lysosmes of cells, where the iron oxide is
broken into iron ions presumably due to hydrolysing enzymes
effective at low pH and ultimately get incorporated into
hemoglobin (57, 67).
Combination of Nanocarriers (SPIONs)
With Chemotherapy
Challenges in routine chemotherapy are systemic toxicities.
Despite several chemotherapeutics have shown the ability to
induce ICD, systemic applications are accompanied by severe
side effects, in particular destruction of the immune system
(11). That’s why some of the current chemotherapeutics are also
used as immunosuppressive agents (e.g., cyclophaosphamide,
methotrexate) for the treatment of severe autoimmune diseases.
By loading chemotherapeutic drugs onto nanoparticles this
challenge can be addressed. With targeting of nanoparticles
to the tumor region, the systemic concentration is reduced
while effective intratumoral doses are increased. Several
chemotherapeutic agents such as doxorubicin, daunorubicin,
or vincristine encapsulated into (PEGylated) liposomes have
been approved as e.g., Doxil R©/Caelyx R©, DaunoXome R©, or
Marqibo, respectively. Paclitaxel bound to lyophilized human
albumin as carrier protein is registered as Abraxane R© for
breast cancer treatment (68). Presensitization of tumor cells
with antisense miRNA (against miRNAs expressed during
cancer) or siRNA (against a developmental transcription factor
reactivated in cancers) prior to chemotherapy can reduce the
effective doses of chemotherapeutics needed or can overcome
chemoresistance (69, 70).
To induce anti-tumor immune reactions, inducers of ICD
such as oxaliplatin or doxorubicin have been loaded into
nanocarriers (71–74). Exemplarily, after intravenous injection
of oxaliplatin or doxorubicin-loaded amphiphilic diblock
copolymer nanoparticles, the nanoparticle-encapsulated ICD
inducer led to significantly enhanced ICD and consequently
improved anti-tumor effects in pancreatic cancer xenograft
compared to the free form (71). Active targeting of
nanoformulations using magnetic forces have been explored to
maximize drug accumulation of ICD inducers as well. We and
others loaded chemotherapeutic drugs such as mitoxantrone or
doxorubicin onto SPIONs and showed improved targeting and
anti-tumor efficacy in the presence of magnetic fields in vivo
(44, 75, 76). When we treated rabbits suffering from induced
squamous cell carcinomas with SPIONs functionalized with
mitoxantrone and targeted the particles to the tumor by an
external magnet, the tumors were continuously shrinking until
complete tumor disappearance after several weeks, indicating
rather an immunological process than immediate tumor lysis by
mitoxantrone (44). We proved that mitoxantrone functionalized
SPIONs can induce ICD with concomitant release of DAMPs
such as HSPs, ATP, HMGB1, and foster maturation of DCs (77).
Improving chemotherapy (probably by synergistically
inducing ICD), pH sensitive magnetically guidable iron oxide
nanocarriers loaded with doxorubicin and a photosensibilisator
showed beneficial effects in U87 tumor bearing nude mice, thus
overcoming chemoresistance (78).
Combination of Nanocarriers (SPIONs)
With Immunotherapy
Anti-cancer immunotherapies shall increase the strength of
immune responses against the tumor by either stimulating
activities of the immune system or block signals produced by
cancer cells to suppress immune responses. In the evolving
field of immunotherapy, therapeutic antibodies against tumor
antigens (e.g., Herceptin targeting HER-2/neu on breast cancer)
or antibodies inhibiting the proliferation of tumor-supplying
vessels, stimulatory cytokines (e.g., interferon α and β), and
immune checkpoint inhibition (e.g., PD-1 inhibitors) have shown
clinical activity in many different types of cancer.
Several pathways influence the intensity of an immune
reaction to prevent autoimmune reactions. Inhibitory pathways
induce downregulation of T cell activation or effector functions
(79). T cells with receptors recognizing non-self structures on
tumor cells are the key players to trigger anti-tumor immune
responses. Binding of the T cell receptor accompanied by a co-
stimulatory signal leads to T cell activation. The tight control
of this process is essential to inhibit excessive activation leading
to autoimmune reactions, whereby the proteins CTLA-4 and
PD-1 on T cells play major roles as brakes of T cell activation.
Blocking CTLA-4 and/or PD-1 by antibodies can restore immune
activation, referred to as immune checkpoint therapy (80, 81).
Examples for antibodies that target PD-1 are Pembrolizumab or
Nivolumab, applied in several types of cancer including tumors
of the skin, kidney, bladder, head and neck, lung, and Hodgkin
lymphoma (82).
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Challenges of current immunotherapies are systemic
autoimmune reactions, low response rates, tremendous costs,
and application to patients with compromised immune systems.
Loading immunotherapeutics onto nanoparticulate transporters
can increase their therapeutic potential (83). Thus, currently
nanoparticles are being investigated as transporters for antigens,
adjuvants, or siRNA to activate the immune system (5). To target
nanoparticles to PD-L1 expressing cancer cells, PD-1 antibody
was not only used on nanoparticles as targeting ligand but also
for disturbing the interaction between PD-L1 on tumor cells and
immune cells (84).
Tumor accumulation of nanoparticulate immunotherapeutics
can further be increased by targeting T cells in the circulation
since leukocytes are the first cells intravenously applied
nanoparticles get in contact with. Additionally, lymphocytes
can deeply penetrate into the tumor tissue. Thus, nanoparticles
targeting PD-1 expressed on T cells and inhibition of TGF-
β signaling have been shown to increase survival of tumor
bearing mice. With this approach dosing can be significantly
reduced, thus limiting potential toxicity (85). In this context first
pilot experiments have been performed to load T cells ex vivo
with SPIONs as transporters for (immune modulatory) drugs to
subsequently inject and guide them to the tumor area using an
external magnetic field (86).
Combination of Nanocarriers (SPIONs)
With Hyperthermia and Radiotherapy
Mild hyperthermia can elicit cell death by denaturation of
proteins and/or damage of DNA and othermechanisms, resulting
in apoptosis (87). Inefficient blood flow and supply with oxygen
through the quickly generated blood vessels in tumors results
in an acidotic and nutrient-deprived milieu making cancer cells
more thermo sensitive to acute increases in temperature than
healthy cells (88). Major problem with conventional methods
to induce hyperthermia is the generation of homogenous
therapeutic temperatures deep in the tumor. Here, SPIONs can
act as controllable heat source: in alternating magnetic fields, the
magnetic polarity rapidly flips. However, there is some hysteretic
loss involved in the flipping, revealing as heat. Thus, a tumor
can be heated in alternating magnetic fields if preloaded with
SPIONs. Although there are some reports on use of magnetic
hyperthermia alone to treat and/or cure cancer in animal
models, magnetic hyperthermia is often used in combination.
Radiotherapy and hyperthermia have complementary effects:
Poorly perfused tumor cores are sensitive to hyperthermia but
resistant to ionizing radiation which depends on the formation of
toxic oxygen radicals in well perfused areas. Also, in the S phase
of the cell cycle tumor cells exhibit radioresistancy, but are highly
sensitive to heat. Thus, hyperthermia can act as radiosensitizer to
radioresistant cancer cells (89).
Radiosensitizers, such as histone deacetylase inhibitors,
which inhibit DNA double strand repair can enhance the
response of tumor cells to radiation through the prolongation
of γ-H2AX foci as shown with polymer nanoparticles (90).
Also, binding of radionuclids to SPIONs, particularly β
emitters, induced DNA damage due to free radicals, resulting
in apoptosis of target cells (91). Also, SPIONs have shown
their potential as X ray-enhancer for low-dose irradiation
therapy. After radiation the amount of toxic ROS in
tumor cells with engulfed nanoparticles has substantially
increased (92, 93).
SUMMARY
For efficient cancer treatment including long-term immune
reactions, the immunogenicity of the tumor must be increased
and the tolerance of the immune system against tumor associated
antigens abrogated. Importantly, at the same time, immune
compatibility has to be preserved.With nanoparticles as platform
technology immunotherapeutics and/or chemotherapeutic drugs
can be targeted towards the tumor. Compared to systemic
application, the intratumoral drug concentration can be
increased and healthy tissues spared from the drug related
side effects by nanoparticle-mediated transportation (Figure 1B).
Concurrent radiation and/or hyperthermia of the tumor induces
cell death and increases immunogenicity of the tumor cells.
Employing SPIONs as drug transporters enables multimodal
therapy concepts since compounds of various therapeutic
classes (e.g., chemotherapeutics, immunemodulators, phototoxic
compounds) can be bound and adapted to the individual
profile of the patient. Using SPIONs as nanoparticle platform
additionally enables monitoring of tumor targeting in MRI
(Theranostics) (62, 63).
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